9.90Open9.90Pre Close0 Volume58 Open Interest12.50Strike Price0.00Turnover0.00%IV15.17%PremiumJan 17, 2025Expiry Date6.95Intrinsic Value100Multiplier13DDays to Expiry2.95Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma2.86Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Grail Stock Discussion
Larger Image: tradingview.com...
$Grail (GRAL.US)$
GRAIL Advances the Galleri® Registrational Clinical Trial Program
GRAIL (NASDAQ: GRAL) has announced significant progress in its clinical trials for the Galleri® multi-cancer early detection (MCED) test. The company has completed enrollment of over 35,000 participants in the PATHFINDER 2 study across North America and finished the final study visits for the NHS-Galleri trial with more than 140,000 participants in England. Results from the first 25,000 PATHFINDER 2 participan...
No comment yet